Schedule 13G ownership disclosure

AN2 Therapeutics, Inc.

Common Stock · CUSIP: 037326105

Event date: 2024-12-31

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Frazier Life Sciences Public Fund, L.P.

    Shares: 0.00 · Class: 0.0%

  • FHMLSP, L.P.

    Shares: 0.00 · Class: 0.0%

  • FHMLSP, L.L.C.

    Shares: 0.00 · Class: 0.0%

  • Frazier Life Sciences X, L.P.

    Shares: 0.00 · Class: 0.0%

  • FHMLS X, L.P.

    Shares: 0.00 · Class: 0.0%

  • FHMLS X, L.L.C.

    Shares: 0.00 · Class: 0.0%

  • Frazier Life Sciences XI, L.P.

    Shares: 0.00 · Class: 0.0%

  • FHMLS XI, L.P.

    Shares: 0.00 · Class: 0.0%

  • FHMLS XI, L.L.C.

    Shares: 0.00 · Class: 0.0%

  • James N. Topper

    Shares: 0.00 · Class: 0.0%

  • Patrick J. Heron

    Shares: 0.00 · Class: 0.0%

  • Albert Cha

    Shares: 0.00 · Class: 0.0%

  • James Brush

    Shares: 0.00 · Class: 0.0%

  • Daniel Estes

    Shares: 0.00 · Class: 0.0%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001415889-25-003979
Form type
SCHEDULE 13G/A
Filer
AN2 Therapeutics, Inc.
CIK
CIK 1880438
Filed
Feb 14, 2025
Reporting period
Dec 31, 2024
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub